Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer
- 1 December 1988
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 114 (6) , 602-604
- https://doi.org/10.1007/bf00398184
Abstract
Twenty-six cycles of high-dose ifosfamide+mesna (HD-IFO+M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO+M over 24 h appeared to be the best tolerated. On partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.Keywords
This publication has 14 references indexed in Scilit:
- Ifosfamide/mesna and hematuria.1987
- Ifosfamide-pharmacology, safety and therapeutic potentialCancer Treatment Reviews, 1985
- IFOSFAMIDE/MESNA AND ENCEPHALOPATHYThe Lancet, 1985
- High-dose ifosfamide and mesna as continuous infusion over five days—a phase I/II trialCancer Treatment Reviews, 1983
- Central nervous side effects following ifosfamide monotherapy of advanced renal carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 1981
- Reporting results of cancer treatmentCancer, 1981
- PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMAThe Lancet, 1980
- Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).1976
- Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.1976
- Unexpected toxicity in patients treated with iphosphamide.1972